TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23924691

Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation (4.5 g daily for 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation
Number of subjects: 100
Study: 21650086

Group type: EXPERIMENTAL
Intervention: 250 mg ascorbic acid (Vit. C)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 19526424

Group type: EXPERIMENTAL
Intervention: Nicotine patch (15 mg/16 h)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nasal spray (recommended regimen of 24 doses per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16946104

Group type: EXPERIMENTAL
Intervention: R406 (spleen tyrosine kinase inhibitor)
Number of subjects: 0
Study: 14738831

Group type: EXPERIMENTAL
Intervention: Xtra White (XW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colgate Simply White (CSW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study: 10696400

Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains
Number of subjects: 84
Study: 8933645

Group type: EXPERIMENTAL
Intervention: Erythritol (0.3 g/kg on Day 1, 0.6 g/kg on Day 2, 1.0 g/kg on Days 3-7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 12
Study: 1808616

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg every 4 hr for eight doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline tablets after ranitidine pretreatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate-release tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sustained-release theophylline tablets
Number of subjects: 12
Study: 6412583

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin preparation containing oil and alum monostearate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzylpenicillin preparation without oil and alum monostearate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin preparation without adjuvants initiated by benzylpenicillin preparation containing oil and alum monostearate
Number of subjects: 0
Study: 31079567

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (5 mg in 100 ml) applied on the 5th day after ACDF surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no zoledronic acid)
Number of subjects: 43
Study: 30012135

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27283863

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study: 24740528

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Midazolam (0.045 mg/kg)
Number of subjects: 41
Study: 23131727

Group type: EXPERIMENTAL
Intervention: Adapted English Version (AEV) of SS-QoL 2.0
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Yoruba Version (YV) of SS-QoL 2.0
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both AEV and YV
Number of subjects: 35
Study: 20945946

Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg twice daily for 10-14 days (long-term group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Edaravone 30 mg twice daily for 3 days (short-term group)
Number of subjects: 47
Study: 18720535

Group type: EXPERIMENTAL
Intervention: Herbal formulation (Curcuma longa and Tinospora cordifolia)
Number of subjects: 508
Study: 15889523

Group type: EXPERIMENTAL
Intervention: TCM drugs
Number of subjects: 121

Group type: COMPARATOR
Intervention: Estazolam (Control)
Number of subjects: 121
Study: 12817155

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 10535343

Group type: EXPERIMENTAL
Intervention: 400 mg mifepristone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8697846

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy discontinued
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (continued chest physiotherapy)
Number of subjects: 101
Study: 1816187

Group type: EXPERIMENTAL
Intervention: Intermittent infusion (10 mg/kg/6 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous infusion (10 mg/kg/6 h)
Number of subjects: 8
Study: 6355053

Group type: COMPARATOR
Intervention: Acyclovir cream for initial genital herpes
Number of subjects: 185

Group type: COMPARATOR
Intervention: Acyclovir cream for recurrent genital herpes
Number of subjects: 185
Study: 30693660

Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate fluoride varnish
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 10.6 μm CO2 laser
Number of subjects: 3

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 3
Study: 28098519

Group type: EXPERIMENTAL
Intervention: Knowledge rating condition
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High belief in certainty of knowledge
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tendency to maximization
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High need for cognition
Number of subjects: 123
Study: 27134133

Group type: EXPERIMENTAL
Intervention: Passive intermittent normobaric hypoxia (IH) for 90min followed by 30min of aerobic training three times per week for four weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ambient air followed by 30min of aerobic training three times per week for four weeks
Number of subjects: 34
Study: 24916419

Group type: EXPERIMENTAL
Intervention: Test dental gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control dental gel
Number of subjects: 25
Study: 23114940

Group type: EXPERIMENTAL
Intervention: Six month intervention
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: 18 month follow-up intervention
Number of subjects: 532
Study: 19461584

Group type: EXPERIMENTAL
Intervention: Cetilistat 80 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetilistat 120 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetilistat 40 mg t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17425687

Group type: EXPERIMENTAL
Intervention: Standard doses of enoxaparin (30 mg b.i.d. or 40 mg o.d.)
Number of subjects: 5796

Group type: COMPARATOR
Intervention: No venography
Number of subjects: 5796

Group type: EXPERIMENTAL
Intervention: Venography reading committee (Gothenburg vs. Hamilton)
Number of subjects: 5796
Study: 15681310

Group type: EXPERIMENTAL
Intervention: Behavioral-educational intervention (girls only, n = 73)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Behavioral-educational intervention (girls with mothers, n = 94)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Healthy-lifestyles control group (n = 80)
Number of subjects: 247
Study: 12127465

Group type: EXPERIMENTAL
Intervention: UCC plus an assertive continuing care protocol (ACC) involving case management and the adolescent community reinforcement approach
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: UCC plus an assertive continuing care protocol (ACC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual continuing care (UCC)
Number of subjects: 114
Study: 10522717

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (mild to moderate alcohol problems)
Number of subjects: 1153
Study: 8245337

Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral disopyramide (800 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: No pharmacological treatment (control)
Number of subjects: 22
Study: 3084442

Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment applied four times a day for five days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Number of subjects: 32
Study: 31678185

Group type: EXPERIMENTAL
Intervention: Host-associated probiotic (HAP) Enterococcus faecium strain CGMCC1.2136, 108 CFU g-1
Number of subjects: 270

Group type: COMPARATOR
Intervention: Commercial probiotic (CP) Pediococcus acidilactici, 107 CFU g-1
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (basal diet without bacterial supplementation)
Number of subjects: 270
Study: 29740737

Group type: COMPARATOR
Intervention: Paravertebral block (PVB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Modified continuous intercostal block (ICB)
Number of subjects: 50
Study: 27389243

Group type: EXPERIMENTAL
Intervention: Dabigatran (120 U/kg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Dabigatran (130 U/kg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (130 U/kg)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Apixaban (130 U/kg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Warfarin (100 U/kg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Warfarin (control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Dabigatran (control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Apixaban (control)
Number of subjects: 360
Study: 26468076

Group type: EXPERIMENTAL
Intervention: Dietitian delivered behaviour change counselling intervention
Number of subjects: 0
Study: 23034540

Group type: EXPERIMENTAL
Intervention: 12-week low-intensity walking program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (usual sedentary activity)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of exercise training and β-blockade
Number of subjects: 40
Study: 20948520

Group type: EXPERIMENTAL
Intervention: Large portion (820 g of pasta)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Small portion (410 g of pasta)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blindfolded condition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visible condition
Number of subjects: 30
Study: 17565762

Group type: EXPERIMENTAL
Intervention: Milk product fortified with multiple micronutrients and omega-3 fatty acids
Number of subjects: 972

Group type: COMPARATOR
Intervention: Regular powdered milk (Control)
Number of subjects: 972
Study: 16023759

Group type: EXPERIMENTAL
Intervention: Oral aspirin therapy (150mg daily for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No active intervention (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral aspirin therapy
Number of subjects: 24
Study: 12827577

Group type: EXPERIMENTAL
Intervention: Aspirin ingestion within 7 days of surgery
Number of subjects: 1497

Group type: COMPARATOR
Intervention: No aspirin ingestion
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Central venous or peripheral venous infusion of protamine
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Prior exposure to protamine
Number of subjects: 1497
Study: 10846270

Group type: EXPERIMENTAL
Intervention: Cantilever resin-bonded bridges
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fixed-fixed resin-bonded bridges
Number of subjects: 24
Study: 9763056

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg (2x200 mg) once daily for 5 days
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 7874847

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone with resistance exercise for 10 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waist-to-hip ratio (WHR) and subscapular/triceps skinfolds
Number of subjects: 64
Study: 3336209

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (n = 11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (n = 7)
Number of subjects: 18
Study: 29668325

Group type: EXPERIMENTAL
Intervention: α1‐adrenergic blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 28190761

Group type: EXPERIMENTAL
Intervention: FEC-DOC (3 cycles of epirubicin, 5-fluorouracil, and cyclophosphamide followed by 3 cycles of docetaxel)
Number of subjects: 3547

Group type: COMPARATOR
Intervention: DOC-C (6 cycles of docetaxel and cyclophosphamide)
Number of subjects: 3547

Group type: EXPERIMENTAL
Intervention: Both treatment arms (FEC-DOC and DOC-C)
Number of subjects: 3547
Study: 25800686

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV) using a Novalung R100(®) ventilator until the start of weaning.
Number of subjects: 795

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation.
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 795
Study: 23859929

Group type: EXPERIMENTAL
Intervention: Diet (10% weight loss goal)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Moderate‐to‐vigorous aerobic exercise (225 min/week)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Diet+exercise
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control
Number of subjects: 118
Study: 20667273

Group type: EXPERIMENTAL
Intervention: Foveal presentation with no concurrent task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral presentation with perceptual load task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foveal presentation with concurrent task
Number of subjects: 0
Study: 18377636

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment (therapy group) of up to ten treatment sessions focusing on high velocity, low amplitude manipulation of the cervical and thoracic spine, mobilisation, and soft tissue techniques.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Advice promoting self-management and individual instructions focusing on posture and muscle stretch (advice group).
Number of subjects: 300
Study: 16339351

Group type: EXPERIMENTAL
Intervention: Hypoxic group (Hyp) with inspired O2 fraction = 14.5%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxic group (Nor) with inspired O2 fraction = 21%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypoxic group (Hyp)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normoxic group (Nor)
Number of subjects: 15
Study: 15022575

Group type: EXPERIMENTAL
Intervention: Xiclav (amoxicillin + clavulanic acid) administered parenterally i.v. (adults at a dose of 3 x 1.2 gr i.v.; children at a dose of 3 x 30 mg/kg) with early oral switch therapy (adults at a dose of 3 x 625 mg per os; children at a dose of 3 x 25‐50 mg/kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Parenteral regimen without transition to oral dosage form
Number of subjects: 240
Study: 11060951

Group type: EXPERIMENTAL
Intervention: Galloy restorative material
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dispersalloy control material
Number of subjects: 14
Study: 8676798

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pyridoxine (70 mg/day)
Number of subjects: 37
Study: 1563900

Group type: EXPERIMENTAL
Intervention: Brief group psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 0
Study: 3907298

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 4080

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4080
Study: 30801548

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure CNI
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) with standard-exposure CNI
Number of subjects: 2026
Study: 29361967

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (15% CHO, 60% fat, 25% protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat diet (55% CHO, 20% fat, 25% protein)
Number of subjects: 20
Study: 27447365

Group type: EXPERIMENTAL
Intervention: 3,200 repetitions of task-specific upper-limb training
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 9,600 repetitions of task-specific upper-limb training
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Individualized maximum repetitions of task-specific upper-limb training
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 6,400 repetitions of task-specific upper-limb training
Number of subjects: 85
Study: 24652410

Group type: EXPERIMENTAL
Intervention: Biomarker-driven, depletive fluid-management group
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 304
Study: 22328739

Group type: EXPERIMENTAL
Intervention: BMS945429 (80 mg)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: BMS945429 (160 mg)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: BMS945429 (320 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 21049175

Group type: EXPERIMENTAL
Intervention: Steroid therapy (duration: 1 to 7 years)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Natural evolution of DMD (Scott's study)
Number of subjects: 90
Study: 17034006

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose 119.2 +/- 56.4 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 16274152

Group type: EXPERIMENTAL
Intervention: Immediate provisional crown with insertion torque of 20 Ncm
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (implants restored after a healing period)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Insertion torque above 32 Ncm
Number of subjects: 23
Study: 11898006

Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT) with IFA whole body extract (WBE)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT) with IFA WBE
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (no premedication)
Number of subjects: 59
Study: 10414941

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Age-specific diabetes prevalence
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Age-specific IFG prevalence
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Associations with diabetes and IFG
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Comparison with Americans
Number of subjects: 2500
Study: 7583862

Group type: EXPERIMENTAL
Intervention: Theo-24 (anhydrous extended-release capsules) plus inhaled beta 2-agonist
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo plus inhaled beta 2-agonist
Number of subjects: 61
Study: 1965904

Group type: EXPERIMENTAL
Intervention: CCNU plus VM-26 plus 5-FU
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: CCNU plus VM-26
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: CCNU alone
Number of subjects: 173
Study: 347106

Group type: EXPERIMENTAL
Intervention: Levamisole as an immune adjuvant in addition to standard therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 37
Study: 31734121

Group type: EXPERIMENTAL
Intervention: 20 g × 2 whey-enriched protein supplementation
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: isocaloric placebo
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control with no supplementation
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: All intervention groups (including whey and isocaloric)
Number of subjects: 218
Study: 31083000

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia combined with desflurane anaesthesia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Desflurane balanced anaesthesia
Number of subjects: 62
Study: 29084318

Group type: COMPARATOR
Intervention: LOW SFM+
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: HIGH SFM+
Number of subjects: 172
Study: 25427288

Group type: EXPERIMENTAL
Intervention: Bilateral Paravertebral Blockade (PVB) with ropivacaine 0.5%
Number of subjects: 83

Group type: COMPARATOR
Intervention: Incisional Local Anesthetic Administration (port infiltration) with ropivacaine 0.5%
Number of subjects: 83
Study: 23335039

Group type: EXPERIMENTAL
Intervention: Lowest α-tocopherol quartile
Number of subjects: 1046

Group type: COMPARATOR
Intervention: α-tocopherol
Number of subjects: 1046
Study: 22336064

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1.0% combined with Proparacaine Hydrochloride 0.5% (Pro+Cyc group)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1.0% (NS+Cyc group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Atropine 1.0% (used one week later for three days)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1.0%
Number of subjects: 71
Study: 19183462

Group type: EXPERIMENTAL
Intervention: Motivational interviewing training for primary care nurses
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 700
Study: 17168427

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) as a primary endpoint
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Overall quality score of trials
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Correlation with publication year
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Correlation with type of journal
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Correlation with presence of biostatistician
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Correlation with number of participating institutions
Number of subjects: 405
Study: 12739685

Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection (PDLi) with a computerized device (Wand)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional buccal infiltration
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both techniques (PDLi and conventional infiltration)
Number of subjects: 98
Study: 11142541

Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children (SET-C)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Testbusters (active, but nonspecific intervention)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: SET-C
Number of subjects: 67